Anti-Neurofibromin antibody [McNFn27b] - N-terminal (ab178323)

Overview

  • Product name
    Anti-Neurofibromin antibody [McNFn27b] - N-terminal
    See all Neurofibromin primary antibodies
  • Description
    Mouse monoclonal [McNFn27b] to Neurofibromin - N-terminal
  • Tested applications
    Suitable for: WB, ICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human Neurofibromin aa 27-41 (N terminal).
    Sequence:

    QQNTHTKVSTEHNKE


    Database link: P21359

  • Positive control
    • HeLa, NIH 3T3 and U251 cells; Human breast carcinoma and Human stomach tissues.

Properties

Applications

Our Abpromise guarantee covers the use of ab178323 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 10 µg/ml. Detects a band of approximately 240-260 kDa (predicted molecular weight: 319 kDa).
ICC/IF 1/10 - 1/100.
IHC-P Use a concentration of 5 - 10 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • Function
    Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity.
  • Involvement in disease
    Defects in NF1 are the cause of neurofibromatosis type 1 (NF1) [MIM:162200]; also known as von Recklinghausen syndrome. A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.
    Defects in NF1 are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. Germline mutations of NF1 account for the association of JMML with type 1 neurofibromatosis (NF1).
    Defects in NF1 are the cause of Watson syndrome (WS) [MIM:193520]. WS is characterized by the presence of pulmonary stenosis, cafe-au-lait spots, and mental retardation. WS is considered as an atypical form of NF1.
    Defects in NF1 are a cause of familial spinal neurofibromatosis (FSNF) [MIM:162210]. Familial spinal NF is considered to be an alternative form of neurofibromatosis, showing multiple spinal tumors.
    Defects in NF1 are a cause of neurofibromatosis-Noonan syndrome (NFNS) [MIM:601321]. NFNS is characterized by manifestations of both NF1 and Noonan syndrome (NS). NS is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis.
    Defects in NF1 may be a cause of colorectal cancer (CRC) [MIM:114500].
  • Sequence similarities
    Contains 1 CRAL-TRIO domain.
    Contains 1 Ras-GAP domain.
  • Information by UniProt
  • Database links
  • Alternative names
    • DKFZp686J1293 antibody
    • FLJ21220 antibody
    • Neurofibromatosis Noonan syndrome antibody
    • Neurofibromatosis related protein NF 1 antibody
    • Neurofibromatosis related protein NF1 antibody
    • neurofibromatosis type I antibody
    • Neurofibromatosis-related protein NF-1 antibody
    • Neurofibromin 1 antibody
    • Neurofibromin truncated antibody
    • Neurofibromin1 antibody
    • NF 1 antibody
    • NF antibody
    • NF1 antibody
    • NF1_HUMAN antibody
    • NFNS antibody
    • Type 1 Neurofibromatosis antibody
    • von Recklinghausen disease neurofibromin antibody
    • von Recklinghausen disease related protein VRNF antibody
    • VRNF antibody
    • WATS antibody
    • Watson disease related protein WSS antibody
    • Watson syndrome antibody
    • WSS antibody
    see all

Images

  • Immunofluorescent analysis of formaldehyde-fixed U251 cells labeling Neurofibromin with ab178323 at 1/20 dilution (green, left image) or a control (right image) followed with a DyLight-488 conjugated secondary antibody. F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue).

  • Immunohistochemical analysis of deparaffinized Human stomach tissue labeling Neurofibromin with ab178323 at 1/20 dilution or without primary antibody (negative control). Detection was performed using a biotin-conjugated secondary antibody and SA-HRP, followed by colorimetric detection using DAB. Tissues were counterstained with hematoxylin.

  • Immunohistochemical analysis of deparaffinized Human breast carcinoma tissue labeling Neurofibromin with ab178323 at 1/20 dilution or without primary antibody (negative control). Detection was performed using a biotin-conjugated secondary antibody and SA-HRP, followed by colorimetric detection using DAB. Tissues were counterstained with hematoxylin.

  • Immunofluorescent analysis of formaldehyde-fixed NIH 3T3 cells labeling Neurofibromin with ab178323 at 1/20 dilution (green, left image) or a control (right image) followed with a DyLight-488 conjugated secondary antibody. F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue).

  • Immunofluorescent analysis of formaldehyde-fixed HeLa cells labeling Neurofibromin with ab178323 at 1/20 dilution (green, left image) or a control (right image) followed with a DyLight-488 conjugated secondary antibody. F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue).

References

ab178323 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab178323.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up